Ouye Sub-Q Plus: Ultra-High Viscosity HA Filler for Profound Subcutaneous Volumization & Structural Support

Ouye Sub-Q Plus, manufactured by **Medytox Inc.** (South Korea), is an **ultra-high viscosity, high G-prime, monophasic hyaluronic acid (HA) dermal filler** specifically engineered for **deep subcutaneous volumization and structural augmentation** in areas requiring maximum projection and long-lasting correction of severe volume deficits. Presented in a **1.0 ml prefilled syringe**, it contains a **very high concentration (25 mg/ml) of cross-linked HA**, resulting in an exceptionally firm, cohesive gel designed for bolus placement in the deep subcutaneous or supraperiosteal plane. **No lidocaine is integrated**, necessitating comprehensive adjunctive anesthesia.https://skin-reboot.com/

**Core Technology & Properties:**
* **Monophasic NASHA Gel:** Homogeneous, BDDE-cross-linked non-animal HA ensures biocompatibility, stability, and predictable tissue integration. The monophasic nature provides cohesive strength.
* **Ultra-High G-Prime (Elasticity):** Possesses **exceptional lifting capacity, rigidity, and resistance to deformation**, significantly higher than Ouye Deep Plus and most competitors. Ideal for creating substantial projection and supporting heavy tissues.
* **High Cohesivity:** Particles exhibit strong mutual attraction, ensuring structural integrity, minimizing migration, and forming stable volumizing units.
* **Ultra-High Viscosity:** Requires significant injection force. Primarily suited for bolus deposition via cannula; threading is difficult.
* **Large Particle Size:** Optimized for longevity and performance in the deepest tissue layers.

**Mechanism of Action:**
1. **Profound Volumetric Restoration:** Immediately replaces large volumes of lost soft tissue upon injection.
2. **Structural Augmentation & Lifting:** Creates a solid scaffold to lift sagging tissues (e.g., midface, jawline, chin) and restore significant skeletal contours.
3. **Deep Fold & Sulcus Correction:** Physically fills and elevates very deep folds (e.g., severe NLFs, pre-jowl sulcus) and hollows (e.g., temples, cheeks).
4. **Hydration & Framework:** HA binds water and provides a matrix for potential tissue integration.

**Primary Indications:**
* **Severe Midface Volume Loss & Cheek Augmentation:** Restoring significant malar volume and projection (supraperiosteal).
* **Profound Nasolabial Folds (NLFs) & Marionette Lines:** Correcting deep folds requiring maximum lifting power.
* **Chin Augmentation (Major Projection):** Enhancing chin definition and achieving strong forward projection.
* **Jawline Sculpting & Pre-jowl Sulcus (Severe):** Defining the mandibular angle and correcting deep pre-jowl depressions.
* **Temporal Hollowing (Extreme):** Restoring significant volume deficit in the temples.
* **HIV-Related Facial Lipoatrophy:** Addressing severe fat loss in the cheeks and temples.
* **Facial Asymmetry Correction (Major Deficit):** Addressing significant structural volume discrepancies.

**Key Administration Considerations:**
* **Ready-to-Use:** No reconstitution required. Prime syringe carefully – high resistance.
* **Anesthesia:** **Mandatory:** Requires adjunctive anesthesia (topical cream + nerve block/local infiltration). No integrated anesthetic.
* **Technique:** **Exclusively bolus or micro-bolus deposition**:
* **Needles:** **Not recommended** due to high vascular risk and difficulty injecting.
* **Cannulas:** **Essential.** Use robust, large-bore blunt cannulas (e.g., **22-25G**, 38-50mm or longer) for safe supraperiosteal/subcutaneous placement. High injection force required.
* **Depth:** **Deep subcutaneous tissue or supraperiosteal plane.** *Must be deep.* Superficial placement causes severe complications.
* **Volume:** Small-to-moderate boluses per point. Gradual layering essential. Avoid overcorrection.
* **Post-Treatment:** Significant swelling, tenderness, bruising, and potential lumpiness are common. Avoid pressure/massage.
* **Longevity:** Results typically last **18 months or longer**, reflecting its ultra-high HA concentration, robust cross-linking, and deep placement.
* **Safety:** **Highest-risk product category.** **Critical Risks:** **Vascular Occlusion/Compression & Embolism** (potentially catastrophic). **Requires expert injectors** with profound anatomical knowledge, cannula use, aspiration (if needle *must* be used), small bolus volumes, and extreme caution. High risk of **palpable or visible nodules/lumps** if technique poor or placement incorrect. Granuloma risk (rare). Tyndall effect unlikely.
* **Regulatory Status:** **CE marked** (Europe/international). **Not FDA-approved in the USA.**
* **Prescription:** Prescription medical device.

Ouye Sub-Q Plus is a potent volumizer reserved for experienced injectors correcting the most severe deficits, leveraging ultra-high viscosity HA for unparalleled structural support and longevity, demanding meticulous deep cannula technique and rigorous safety protocols.CONTACT US

The post Ouye Sub-Q Plus first appeared on Svelte Path.